Akèy › Kansè Glann Salivè
Etid klinik pou Kansè Glann Salivè ap rekrite nan Etazini
15 etid pou Kansè Glann Salivè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Nashville, TN5 etid
- Houston, TX5 etid
- Boston, MA5 etid
- New York City, NY4 etid
- Philadelphia, PA3 etid
- Dallas, TX3 etid
- Highlands Ranch, CO3 etid
Pa eta
- Colorado5 etid
- Florid4 etid
- Illinois4 etid
- Kalifòni4 etid
- Kansas3 etid
- Massachusetts6 etid
- Minnesota3 etid
- New Jersey3 etid
- New Mexico3 etid
- New York5 etid
- Ohio4 etid
- Pennsylvania4 etid
- Tennessee5 etid
- Texas6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05408845Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT05884320A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Oropharynx (OPX) Biomarker Trial
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT06356272Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT04620187Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2026 · NCT03740256Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jan 26, 2026 · NCT05553782VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Dec 11, 2025 · NCT03556228Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 28, 2025 · NCT00898638A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Ap rekriteEtid obsèvasyon
Laj 21 a 90 · Tout sèks · Mizajou Sep 22, 2025 · NCT00900419Physiologic MR Imaging of Salivary Gland Tumors
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT04452162A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2025 · NCT06805617Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.